Search Result
19 search results for Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma, NCCN clinical practice guidelines in oncology – Pancreatic Adenocarcinoma
https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdfNCCN Guidelines Pancreatic Adenocarcinoma
NCCN Guidelines Pancreatic Adenocarcinoma, NCCN clinical practice guidelines in oncology – Pancreatic Adenocarcinoma
https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdfPermission to Cite or Use NCCN Content
Peritoneal Cancer Palliative Care Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia, Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric, Adenocarcinoma Anal Carcinoma Antiemesis Basal Cell Skin Cancer B-Cell Lymphomas Biliary Tract, Assessment: Breast, Ovarian, and Pancreatic Genetic/Familial High-Risk Assessment: Colorectal Gestational, Oncology Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Palliative Care Pancreatic
https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-contentTransparency Process
Version: 4.2024 ( Small Bowel Adenocarcinoma ) Date: 2024-06-21 Transparency, Adenocarcinoma ) Date: 2024-04-17 Transparency Document Panel Disclosures/Attendance, Panel Disclosures/Attendance Version: 2.2024 ( Small Bowel Adenocarcinoma ) Date, Version: 1.2024 ( Small Bowel Adenocarcinoma ) Date: 2023-08-28 Transparency Document, ( Small Bowel Adenocarcinoma ) Date: 2022-08-31 Transparency Document Panel Disclosures
https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendationsResume Screening
Cancer/Primary Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Ampullary Adenocarcinoma Anal Carcinoma, Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Genetic/Familial High-Risk, and Locally Advanced Non-Small Cell Lung Cancer - Metastatic Ovarian Cancer Palliative Care Pancreatic
https://www.nccn.org/covid-19/resume-screeningSubmission Request Form
Adolescent and Young Adult (AYA) Oncology - 1.2025 Adult Cancer Pain - 2.2024 Ampullary Adenocarcinoma, /Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic - 3.2024 Genetic/Familial High-Risk, Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer - 3.2024 Palliative Care - 1.2024 Pancreatic Adenocarcinoma - 2.2024 Pediatric Acute Lymphoblastic Leukemia - 6.2024 Pediatric Aggressive, Detection - 2.2024 Rectal Cancer - 3.2024 Small Bowel Adenocarcinoma - 4.2024 Small Cell Lung Cancer
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-formTreatment by Cancer Type
Version: 3.2024 Ampullary Adenocarcinoma, Cancer Version: 3.2024 Pancreatic Adenocarcinoma Version: 2.2024 Pediatric Acute, Small Bowel Adenocarcinoma Version: 4.2024
https://www.nccn.org/guidelines/category_1Guidelines Panels
Panel Pancreatic Adenocarcinoma Panel, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel
https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panelsHarmonized Guidelines
Version 2.2023 Pancreatic Adenocarcinoma Version 2.2022 Pediatric Acute
https://www.nccn.org/global/what-we-do/harmonized-guidelinesClinical Guidelines Translations
) Pancreatic Adenocarcinoma Version 2.2021 (Japanese) Waldenström
https://www.nccn.org/global/what-we-do/clinical-guidelines-translationsGuidelines for Patients
Version: 2023 Pancreatic Cancer, Version: 2024 Small Bowel Adenocarcinoma
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patientsGuidelines for Patients
Pancreatic Cancer Version: 2023, Small Bowel Adenocarcinoma Version: 2024
https://www.nccn.org/guidelines/patientsORP Grant History
with Advanced Pancreatic Cancer Renuka Iyer, MD Roswell Park Comprehensive Cancer Center Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer Nikhil, Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic and Biliary Carcinomas Daniel Laheru, MD, -Directed Phase II Trial of Oral Capecitabine for 2nd Line Treatment of Advanced Pancreatic Cancer Mary, Adenocarcinoma Lakshmi Pendyala, PhD Roswell Park Comprehensive Cancer Center Gene Expression Profiling
https://www.nccn.org/education-research/nccn-oncology-research-program/orp-grant-historyGuidelines With Evidence Blocks
Pancreatic Adenocarcinoma Version 2.2024 Pediatric Acute Lymphoblastic Leukemia, Leukemia Version 4.2023 Acute Myeloid Leukemia Version 3.2024 Ampullary Adenocarcinoma, Adenocarcinoma Version 3.2024 Small Cell Lung Cancer Version 3.2024 Soft Tissue Sarcoma
https://www.nccn.org/guidelines/guidelines-with-evidence-blocksFramework for Resource Stratification
3.2022 NCCN Guidelines Version 7.2024 Pancreatic Adenocarcinoma Basic
https://www.nccn.org/global/what-we-do/nccn-framework-for-resource-stratification-of-nccn-guidelinesScientific Publications
adenocarcinoma (EGAC): Preliminary results from a phase II study [abstract]. In: Proceedings of the American, Junction Adenocarcinoma (EGAC)Journal of Clinical Oncology 38, no. 4_suppl. Published on line, ) in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors (PNETs) (NCT01465659). J Clin, and carboplatin for advanced and recurrent endometrioid endometrial adenocarcinoma. SUNDAY_2021- SGO
https://www.nccn.org/education-research/nccn-oncology-research-program/scientific-publicationsChemotherapy Order Templates Reviewer Acknowledgement
at the University of Pennsylvania Pancreatic Adenocarcinoma Sally Barbour, and Washington University School of Medicine Ampullary Adenocarcinoma, and Solove Research Institute Small Bowel Adenocarcinoma Courtney
https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagementSubmission Request History
Adenocarcinoma Submitted by Merck & Co., Inc. on 03/20/2020 Pembrolizumab Submitted by Merck, . on 06/10/2020 Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc, (TMB) for Small Bowel Adenocarcinoma Submitted by Foundation Medicine, Inc. on 09/16/2020, Submitted by GlaxoSmithKline on 08/17/2021 Dostarlimab-gxly for Small Bowel Adenocarcinoma, Nivolumab + ipilimumab for Small Bowel Adenocarcinoma Submitted by Bristol-Myers Squibb
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-history